ClinicalTrials.gg
CompletedNCT00553280Updated Jan 25, 2021Results posted

A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy

A Phase 3 interventional study of pregabalin in Diabetic Neuropathy, Painful, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 27 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
123
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies testing pregabalin in Diabetic Neuropathies — 1 open to participants now, 1 under way, 1 of them phase 3. Pregabalin · Diabetic Neuropathies.

Enrollment
14th of 17
123 · median 241
Started
2008
the only one that year
Phase 3
10 of 17
1 open now
Registered
7th of 17
by date
Lead sponsor
9 of 17
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 17 studies testing pregabalin in Diabetic Neuropathies, this one is the 14th largest by enrollment, is the only one that started in 2008, is one of 10 in phase 3, and was the 7th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

1 of the 17 studies testing pregabalin in Diabetic Neuropathies is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing pregabalin in Diabetic Neuropathies, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of the long-term use of pregabalin at doses up to 600 mg/day in patients with painful diabetic peripheral neuropathy who have completed 13 weeks of dosing in Study A0081163

03

Conditions studied

  • Diabetic Neuropathy, Painful

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed the 13-week treatment of painful diabetic peripheral neuropathy in Study A0081163.
  • Patients must be able to understand and cooperate with study procedures and have signed a written prior to entering the study

Exclusion criteria

Exclusion Criteria:

  • Patients who experienced serious adverse events in the preceding study (A0081163) that were determined by the investigator or the study sponsor to be causally related to the study medication.
  • Patients exhibiting treatment non-compliance in the preceding study (A0081163)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    pregabalin

    Drug: pregabalin

Interventions

  • Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks

06

What researchers measure

Primary outcomes

  1. Summary of Adverse Events

    Number of participants with all causality adverse events, serious adverse events, severe adverse events, adverse events resulted in discontinuation, dose reduced or temporary discontinuation. Participants are counted only once per treatment in each row.

    Time frame: 53 weeks

Secondary outcomes

  1. Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores

    The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain.

    Time frame: From baseline to 52 weeks or study discontinuation (Study Endpoint)

  2. Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores

    The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain.

    Time frame: From baseline to 52 weeks or study discontinuation (Study Endpoint)

  3. Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores

    The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain.

    Time frame: From baseline to 52 weeks or study discontinuation (Study Endpoint)

  4. Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores

    The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain.

    Time frame: From baseline to 52 weeks or study discontinuation (Study Endpoint)

  5. Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores

    The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain.

    Time frame: From baseline to 52 weeks or study discontinuation (Study Endpoint)

07

Results

Posted Jan 5, 2011

Participant flow

Thirty-six (36) centers in Japan

Participant flow — Overall Study
MilestonePregabalin
Started123
Completed97
Not completed26
Withdrew: Adverse event19
Withdrew: Lack of efficacy3
Withdrew: Withdrawal by subject3
Withdrew: Physician decision1

Outcome measures

PrimarySummary of Adverse Events

Number of participants with all causality adverse events, serious adverse events, severe adverse events, adverse events resulted in discontinuation, dose reduced or temporary discontinuation. Participants are counted only once per treatment in each row.

Time frame:
53 weeks
Reported as:
Number · participants
Summary of Adverse Events
participantsPregabalin
Participants with adverse events114
Participants with serious adverse events21
Participants with severe adverse events7
Participants discontinued due to adverse events17
Dose reduced or temporary discontinuation43
SecondaryChange From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Sensory score ranges from 0-33. Higher scores indicate more severe pain.

Time frame:
From baseline to 52 weeks or study discontinuation (Study Endpoint)
Reported as:
Mean · score on scale
Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores
score on scalePregabalin
Change From Baseline in Short-Form McGill Pain Questionnaire: Sensory Scores-3.5 ± 5.1
SecondaryChange From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Affective score ranges from 0-12. Higher scores indicate more severe pain.

Time frame:
From baseline to 52 weeks or study discontinuation (Study Endpoint)
Reported as:
Mean · score on scale
Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores
score on scalePregabalin
Change From Baseline in Short-Form McGill Pain Questionnaire: Affective Scores-1.2 ± 2.4
SecondaryChange From Baseline in Short-Form McGill Pain Questionnaire: Total Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Total score ranges from 0-45. Higher scores indicate more severe pain.

Time frame:
From baseline to 52 weeks or study discontinuation (Study Endpoint)
Reported as:
Mean · score on scale
Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores
score on scalePregabalin
Change From Baseline in Short-Form McGill Pain Questionnaire: Total Scores-4.7 ± 6.8
SecondaryChange From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Visual Analogue Scale Score ranges from 0-100 mm. Higher scores indicate more severe pain.

Time frame:
From baseline to 52 weeks or study discontinuation (Study Endpoint)
Reported as:
Mean · mm
Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores
mmPregabalin
Change From Baseline in Short-Form McGill Pain Questionnaire: Visual Analogue Scale Scores-25.4 ± 26.4
SecondaryChange From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores

The mean change from baseline in Short-Form McGill Pain Questionnaire Scores at study endpoint. Present pain intensity score ranges from 0-5. Higher scores indicate more severe pain.

Time frame:
From baseline to 52 weeks or study discontinuation (Study Endpoint)
Reported as:
Mean · score on scale
Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores
score on scalePregabalin
Change From Baseline in Short-Form McGill Pain Questionnaire: Present Pain Intensity Scores-0.7 ± 1.1

Adverse events

Collected over 53 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—21/123 (17.1%)101/123 (82.1%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventPregabalin
PneumoniaInfections and infestations3/123
CellulitisInfections and infestations2/123
Cerebral infarctionNervous system disorders2/123
Atrioventricular block completeCardiac disorders1/123
Meniere's diseaseEar and labyrinth disorders1/123
Diabetic gangreneInfections and infestations1/123
Femoral neck fractureInjury, poisoning and procedural complications1/123
Femur fractureInjury, poisoning and procedural complications1/123
Hand fractureInjury, poisoning and procedural complications1/123
Thermal burnInjury, poisoning and procedural complications1/123
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPregabalin
NasopharyngitisInfections and infestations39/123
Weight increasedInvestigations35/123
SomnolenceNervous system disorders30/123
DizzinessNervous system disorders29/123
Oedema peripheralGeneral disorders21/123
FallInjury, poisoning and procedural complications14/123
ConstipationGastrointestinal disorders11/123
Face oedemaGeneral disorders10/123
EczemaSkin and subcutaneous tissue disorders10/123
Diabetic retinopathyEye disorders9/123

Baseline characteristics

Age, Customized
Age, Customized(participants)Pregabalin
< 18 years0
18 - 44 years6
45 - 64 years71
>= 65 years46
Age, Customized
Age, Customized(years)Pregabalin
Mean61.7 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin
Female23
Male100
08

Study locations

27 sites
  • Pfizer Investigational Site
    Nagoya, Aichi, Japan
  • Pfizer Investigational Site
    Date-shi, Fukushima, Japan
  • Pfizer Investigational Site
    Nihonmatsu, Fukushima, Japan
  • Pfizer Investigational Site
    Shirakawa-shi, Fukushima, Japan
  • Pfizer Investigational Site
    Sukagawa, Fukushima, Japan
  • Pfizer Investigational Site
    Kamakura, Kanagawa, Japan
  • Pfizer Investigational Site
    Yokohama, Kanagawa, Japan
  • Pfizer Investigational Site
    Sendai, Miyagi, Japan
  • Pfizer Investigational Site
    Matsumoto, Nagano, Japan
  • Pfizer Investigational Site
    Ueda, Nagano, Japan
  • Pfizer Investigational Site
    Beppu, Oita, Japan
  • Pfizer Investigational Site
    Yamada, Okayama, Japan
  • Pfizer Investigational Site
    Naha, Okinawa, Japan
  • Pfizer Investigational Site
    Tomishiro, Okinawa, Japan
  • Pfizer Investigational Site
    Urazoe, Okinawa, Japan
  • Pfizer Investigational Site
    Hirano-ku, Osaka, Japan
  • Pfizer Investigational Site
    Suminoe-ku, Osaka, Japan
  • Pfizer Investigational Site
    Sunto-gun, Shizuoka, Japan
  • Pfizer Investigational Site
    Oyama-shi, Tochigi, Japan
  • Pfizer Investigational Site
    Arakawa, Tokyo, Japan
  • Pfizer Investigational Site
    Bunkyo-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Chiyoda-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Ohta-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Shibuya-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Fukuoka, Japan
  • Pfizer Investigational Site
    Oita, Japan
  • Pfizer Investigational Site
    Tokushima, Japan
09

References and documents

Publications

  • Satoh J, Yagihashi S, Baba M, Suzuki M, Arakawa A, Yoshiyama T. Efficacy and safety evaluation of pregabalin treatment over 52 weeks in patients with diabetic neuropathic pain extended after a double-blind placebo-controlled trial. J Diabetes Investig. 2011 Nov 30;2(6):457-63. doi: 10.1111/j.2040-1124.2011.00122.x. PubMed 24843530 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2007
First posted
Nov 4, 2007
Start
Feb 2008
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Jan 5, 2011
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00553280
Responsible party
Sponsor
First posted
Nov 4, 2007
Start date
Feb 2008
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Jan 5, 2011
Last update
Jan 25, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion